What is the recommended initial management for hypertension?

Initial Management of Hypertension

For most adults with newly diagnosed hypertension, initiate treatment with lifestyle modifications immediately, and start pharmacotherapy with either a thiazide/thiazide-like diuretic, calcium channel blocker (CCB), or ACE inhibitor/ARB—with combination therapy (preferably single-pill) strongly recommended for stage 2 hypertension (BP ≥20/10 mmHg above target). 1

Lifestyle Modifications (First-Line for All Patients)

All patients with elevated blood pressure or hypertension require lifestyle interventions as foundational therapy 2:

• Sodium restriction to <2g/day with increased potassium intake 1
• Weight loss if overweight/obese (BMI ≥25 kg/m²) 2
• Physical activity: regular aerobic exercise 2
• Dietary pattern: DASH diet or Mediterranean-style eating 2
• Alcohol moderation or elimination 2

These interventions are partially additive and enhance medication efficacy, with combined lifestyle changes potentially reducing systolic BP by 10-15 mmHg 2.

Pharmacotherapy Decision Algorithm

When to Start Medication

Stage 1 Hypertension (130-139/80-89 mmHg):

• Start with single-agent therapy if BP goal is <130/80 mmHg 1
• Titrate dosage and add sequential agents as needed 1

Stage 2 Hypertension (≥140/90 mmHg or ≥20/10 mmHg above target):

• Initiate with two first-line agents from different classes, preferably as a fixed-dose combination 1
• This approach achieves faster BP control and higher success rates 1

First-Line Drug Classes

The following are equally acceptable initial choices 1, 2:

1. Thiazide/thiazide-like diuretics (chlorthalidone preferred over hydrochlorothiazide)
2. Calcium channel blockers (e.g., amlodipine)
3. ACE inhibitors (e.g., enalapril)
4. Angiotensin receptor blockers (e.g., candesartan)

Specific Population Considerations

Black patients:

• Initial therapy should include a CCB or thiazide diuretic, either alone or combined with a RAS blocker 1
• ACE inhibitors are less effective as monotherapy in this population for stroke and heart failure prevention 1

Patients with diabetes or CKD (eGFR >30):

• Target systolic BP 120-129 mmHg if tolerated 1
• Include RAS blocker (ACE inhibitor or ARB) if albuminuria or proteinuria present 1

Patients with heart failure:

• HFrEF/HFmrEF: ACE inhibitor (or ARB if intolerant) or ARNI, beta-blocker, MRA, and SGLT2 inhibitor 1
• HFpEF: SGLT2 inhibitors recommended; ARBs/MRAs may be considered 1

Blood Pressure Targets

General adult population <65 years:

• Target <130/80 mmHg 1, 2

Adults ≥65 years:

• Target systolic BP <130 mmHg 2

Patients with prior stroke/TIA:

• Target systolic BP 120-130 mmHg 1

Common Pitfalls to Avoid

Monotherapy overuse: 74% of US Medicare beneficiaries receive monotherapy despite most requiring multiple agents—this leads to inadequate BP control 3. Start combination therapy early in stage 2 hypertension 1.

Beta-blocker as first-line: Beta-blockers are significantly less effective than diuretics for stroke prevention and cardiovascular events, and should not be used as initial monotherapy unless specific indications exist (e.g., heart failure, post-MI) 1.

Alpha-blocker monotherapy: Less effective for CVD prevention than other first-line agents and not recommended as initial therapy 1.

Inadequate BP reduction: A 10 mmHg systolic BP reduction decreases CVD events by 20-30%, so achieving target is critical 2. Most patients require 2-3 medications 4.

Monitoring and Titration

• Home BP monitoring is superior to office measurements for long-term management and correlates better with outcomes 5
• Use the 722 protocol: duplicate readings, twice daily, over 7 consecutive days 5
• Titrate medications every 2-4 weeks until target BP achieved 1
• If target not reached with 3 optimally dosed medications, consider resistant hypertension protocols (add spironolactone) 1